PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $718,218 | -27.5% | 23,410 | -5.4% | 0.05% | -17.5% |
| Q2 2023 | $991,210 | -1.2% | 24,737 | +0.6% | 0.06% | -6.6% |
| Q1 2023 | $1,003,721 | +106678.8% | 24,595 | +1.0% | 0.06% | +5.2% |
| Q4 2022 | $940 | -99.9% | 24,341 | -3.2% | 0.06% | -33.3% |
| Q3 2022 | $1,337,000 | -8.0% | 25,141 | +0.8% | 0.09% | -1.1% |
| Q2 2022 | $1,454,000 | -24.2% | 24,953 | -0.7% | 0.09% | -10.2% |
| Q1 2022 | $1,919,000 | +36.0% | 25,140 | +7.2% | 0.10% | +44.1% |
| Q4 2021 | $1,411,000 | +9.4% | 23,452 | +1.8% | 0.07% | +4.6% |
| Q3 2021 | $1,290,000 | +110.8% | 23,038 | +163.9% | 0.06% | +103.1% |
| Q2 2021 | $612,000 | 0.0% | 8,730 | 0.0% | 0.03% | 0.0% |
| Q1 2021 | $612,000 | +4.6% | 8,730 | -10.8% | 0.03% | 0.0% |
| Q4 2020 | $585,000 | +10.2% | 9,782 | +10.7% | 0.03% | -3.0% |
| Q3 2020 | $531,000 | – | 8,835 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |